BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Israel Police decry online defamation campaign against female officer in Jerusalem- New science points to 4 distinct types of autism
- The Force of Care: Living with Goal
- German state railway loss widens, passengers warned of trouble ahead
- Choosing Moving Styles for Your Restroom Redesign
- Step by step instructions to Protect Your Speculations with Cd Rates
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- Environmental groups urge Germany to cut oil and gas dependence
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
